Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG).

"Competing interests CJW is a consultant for Vigeo Therapeutics and employed at Karyopharm Therapeutics; and has ownership interest in Karyopharm Therapeutics and Bristol-Myers Squibb Co. JSB is a consultant/advisory board member for AbbVie, AstraZeneca, INNATE, KITE. BLP received honoraria from Jazz Pharmaceuticals, Novartis, and Pfizer. JEK has received honoraria from Gilead, Magellan, and Novartis; consulting fees from Gilead, Magellan, Novartis, Pharmacyclics, and Seattle Genetics; institutional research funding from Boehringer Ingelheim, Cantex, Erytech, and Millennium; and travel support from Gilead, Novartis, and Seattle Genetics. JCB has a consultancy/advisory role with Syndax, Novartis, Vincera; research funding from Pharmacyclics LLC, an AbbVie Company, Genentech, Janssen, Acerta; ownership for Vincera. A-KE has a current employment of her spouse at Karyopharm Therapeutics. The other authors declare no competing financial interests."

"This study celebrates the life and accomplishments of Dr. Clara D. Bloomfield (1942–2020), who died unexpectedly on March 1, 2020. The authors are grateful to the patients who consented to participate in these clinical trials and the families who supported them; to Christopher Manring and the CALGB/Alliance Leukemia Tissue Bank at The Ohio State University Comprehensive Cancer Center, Columbus, OH, for sample processing and storage services; and to Lisa J. Sterling for data management. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Research reported in this publication was supported in part by the National Cancer Institute of the National Institutes of Health under Award Numbers U10CA180821, U10CA180882, and U24CA196171 (to the Alliance for Clinical Trials in Oncology), UG1CA233253, UG1CA23318, UG1CA283338, UG1CA189824, UG1CA18985, UG1CA233247, UG1CA233338, U10CA140158, UG1CA233331, U10CA180867, R35CA197734, UG1CA189850, and 5P30CA016058; R01 CA262496 (A-KE, ASM); the Coleman Leukemia Research Foundation; The D Warren Brown Foundation; the Pelotonia Fellowship Program (A-KE), ASH Junior Faculty Scholar and ASH Bridge Award (A-KE); the Leukemia & Lymphoma Society Translational Research Grant (A-KE); The Leukemia Research Foundation (A-KE); The American Cancer Society (A-KE), the National Comprehensive Cancer Network Foundation Young Investigator Award (JSB); the Alliance for Clinical Trials in Oncology Scholar Award (JSB); the Deutsche José Carreras Leukämie-Stiftung DJCLS 10R/2021 (TH); and by an allocation of computing resources from The Ohio Supercomputer Center and Shared Resources (Leukemia Tissue Bank). Support to Alliance for Clinical Trials in Oncology and Alliance Foundation Trials programs is listed at https://acknowledgments.alliancefound.org. Trial registration numbers of companion studies registered at www.clinicaltrials.gov are NCT00048958 (CALGB 8461), NCT00899223 (CALGB 9665) and NCT00900224 (CALGB 20202)."

"This study celebrates the life and accomplishments of Dr. Clara D. Bloomfield (1942–2020), who died unexpectedly on March 1, 2020. The authors are grateful to the patients who consented to participate in these clinical trials and the families who supported them; to Christopher Manring and the CALGB/Alliance Leukemia Tissue Bank at The Ohio State University Comprehensive Cancer Center, Columbus, OH, for sample processing and storage services; and to Lisa J. Sterling for data management. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Research reported in this publication was supported in part by the National Cancer Institute of the National Institutes of Health under Award Numbers U10CA180821, U10CA180882, and U24CA196171 (to the Alliance for Clinical Trials in Oncology), UG1CA233253, UG1CA23318, UG1CA283338, UG1CA189824, UG1CA18985, UG1CA233247, UG1CA233338, U10CA140158, UG1CA233331, U10CA180867, R35CA197734, UG1CA189850, and 5P30CA016058; R01 CA262496 (A-KE, ASM); the Coleman Leukemia Research Foundation; The D Warren Brown Foundation; the Pelotonia Fellowship Program (A-KE), ASH Junior Faculty Scholar and ASH Bridge Award (A-KE); the Leukemia & Lymphoma Society Translational Research Grant (A-KE); The Leukemia Research Foundation (A-KE); The American Cancer Society (A-KE), the National Comprehensive Cancer Network Foundation Young Investigator Award (JSB); the Alliance for Clinical Trials in Oncology Scholar Award (JSB); the Deutsche José Carreras Leukämie-Stiftung DJCLS 10R/2021 (TH); and by an allocation of computing resources from The Ohio Supercomputer Center and Shared Resources (Leukemia Tissue Bank). Support to Alliance for Clinical Trials in Oncology and Alliance Foundation Trials programs is listed at https://acknowledgments.alliancefound.org. Trial registration numbers of companion studies registered at www.clinicaltrials.gov are NCT00048958 (CALGB 8461), NCT00899223 (CALGB 9665) and NCT00900224 (CALGB 20202)."